Online citations, reference lists, and bibliographies.
← Back to Search

Biomarkers In Translational Research Of Alzheimer’s Disease

R. Tarawneh, D. Holtzman
Published 2010 · Psychology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
The identification and characterization of amyloid-beta (Abeta) and tau as the main pathological substrates of Alzheimer's disease (AD) have driven many efforts in search for suitable biomarkers for AD. In the last decade, research in this area has focused on developing a better understanding of the principles that govern protein deposition, mechanisms that link aggregation to toxicity and neuronal death, and a better understanding of protein dynamics in brain tissue, interstitial fluid and CSF. While Abeta and tau represent the two key pathological mediators of disease, other aspects of this multifaceted disease (e.g. oxidative stress, calcium-mediated toxicity, and neuroinflammation) are being unraveled, with the hope to develop a more comprehensive approach in exploring disease mechanisms. This has not only expanded possible areas for disease-modifying therapies, but has also allowed the introduction of novel, and potentially useful, fluid and radiological markers for the presence and progression of AD pathology. There is no doubt that the identification of several fluid and imaging biomarkers that can reliably detect the early stages of AD will have great implications in the design of clinical trials, in the selection of homogenous research populations, and in the assessment of disease outcomes. Markers with good diagnostic specificity will aid researchers in differentiating individuals with preclinical and probable AD from individuals who do not have AD pathology or have other dementing disorders. Markers that change with disease progression may offer utility in assessing the rates of disease progression and the efficacy of potential therapeutic agents on AD pathology. For both of these purposes, CSF Abeta42, amyloid imaging, and CSF tau appear to be very good markers of the presence of AD pathology as well as predictive of who will progress from MCI to AD. Volumetric MRI is also good at separating individuals with MCI and AD from controls and is predictive of who will progress from MCI to AD. Perhaps the most important role biomarkers will have, and the most needed at this time, lies in the identification of individuals who are cognitively normal, and yet have evidence of AD pathology (i.e. preclinical AD). Such individuals, it appears, can be identified with CSF Abeta42, amyloid imaging, and CSF tau. Such individuals are the most likely to benefit from future disease modifying/prevention therapies as they become available, and therefore represent the population in which the field can make the biggest therapeutic impact.
This paper references
10.1111/j.1365-2990.1988.tb00864.x
Neuropil Threads Occur in Dendrites of Tangle—Bearing Nerve Cells
H. Braak (1988)
10.1212/WNL.41.4.469
Very mild Alzheimer's disease
J. Morris (1991)
The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation.
M. D. de Leon (1993)
10.1016/0092-8674(93)90312-E
Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide
C. Haass (1993)
10.1002/CNE.903340203
Evidence that transmitter‐containing dystrophic neurites precede paired helical filament and Alz‐50 formation within senile plaques in the amygdala of nondemented elderly and patients with Alzheimer's disease
W. Benzing (1993)
A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET.
S. Minoshima (1995)
10.1159/000106891
Glial fibrillary acidic protein in the cerebrospinal fluid of patients with dementia.
A. Wallin (1996)
10.1523/JNEUROSCI.16-14-04491.1996
Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease
T. Gómez-Isla (1996)
10.1006/BBRC.1997.6908
Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology.
H. Arai (1997)
10.1016/S0197-4580(97)00051-1
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories
W. Silverman (1997)
Elevated cerebrospinal fluid tau protein level as a predictor of dementia in memory-impaired individuals
H. Arai (1997)
10.1002/ANA.410410106
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
T. Gómez-Isla (1997)
10.1212/WNL.51.4.993
Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease
C. Jack (1998)
10.1016/S0962-8924(98)01368-3
Tau in Alzheimer's disease.
E. Mandelkow (1998)
10.1016/S0197-4580(98)00074-8
Life-long overexpression of S100β in Down’s syndrome: implications for Alzheimer pathogenesis
W.S.T. Griffin (1998)
10.1016/S0022-510X(98)00122-1
Combination assay of CSF Tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease
M. Shoji (1998)
10.1016/S0306-4522(99)00476-5
The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease
M. Bobinski (1999)
10.1212/WNL.52.7.1397
Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment
C.R. Jack (1999)
10.1111/j.1750-3639.1999.tb00215.x
Oxidative Alterations in Alzheimer's Disease
W. Markesbery (1999)
10.1016/S0304-3940(99)00406-1
Alterations of 3-nitrotyrosine concentration in the cerebrospinal fluid during aging and in patients with Alzheimer's disease
H. Tohgi (1999)
10.1016/S0002-9440(10)65185-1
The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients.
T. Montine (1999)
10.1016/S0006-3223(99)00143-2
Longitudinal stability of CSF tau levels in Alzheimer patients
T. Sunderland (1999)
10.1046/J.1471-4159.1999.0720771.X
Increased DNA Oxidation and Decreased Levels of Repair Products in Alzheimer's Disease Ventricular CSF
M. Lovell (1999)
10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X
Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease
J. Price (1999)
10.1006/exnr.2000.7501
CSF Phosphorylated Tau Protein and Mild Cognitive Impairment: A Prospective Study
H. Arai (2000)
10.1016/S0165-0173(00)00019-9
Tau protein isoforms, phosphorylation and role in neurodegenerative disorders 1 1 These authors contributed equally to this work.
L. Buée (2000)
10.1016/S0006-3223(99)00167-5
Hippocampus in Alzheimer’s disease: a 3-year follow-up MRI study
M. Laakso (2000)
10.1016/S0197-4580(99)00107-4
Atrophy of the medial occipitotemporal, inferior, and middle temporal gyri in non-demented elderly predict decline to Alzheimer’s disease☆
A. Convit (2000)
10.1016/S0188-4409(01)00316-2
The molecular bases of Alzheimer's disease and other neurodegenerative disorders.
R. Maccioni (2001)
10.1073/pnas.081620098
Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo
K. Fassbender (2001)
10.1016/S0304-3940(00)01697-9
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke
C. Hesse (2001)
10.1001/ARCHNEUR.58.9.1395
Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease.
J. Price (2001)
10.1043/0003-9985(2001)125<0510:CFATAF>2.0.CO;2
Cerebrospinal Fluid Aβ42, Tau, and F2-Isoprostane Concentrations in Patients With Alzheimer Disease, Other Dementias, and in Age-Matched Controls
T. Montine (2001)
10.1006/nimg.2001.0848
In Vivo Mapping of Gray Matter Loss with Voxel-Based Morphometry in Mild Alzheimer's Disease
J. Baron (2001)
10.1016/S0197-4580(00)00245-1
Synaptic loss and pathological change in older adults—aging versus disease?
J. Price (2001)
10.1126/SCIENCE.1062097
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
J. Götz (2001)
10.1073/pnas.191044198
Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET)
M. D. de Leon (2001)
10.1097/00004691-200103000-00010
Correlation Between Cortical &thgr; Activity and Hippocampal Volumes in Health, Mild Cognitive Impairment, and Mild Dementia
M. Grunwald (2001)
10.1212/WNL.56.7.950
SPECT perfusion imaging in the diagnosis of Alzheimer’s disease
W. Jagust (2001)
10.1038/35094500
Searching for a baseline: Functional imaging and the resting human brain
D. Gusnard (2001)
10.1126/SCIENCE.1058189
Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP
Jada Lewis (2001)
10.1001/JAMA.286.17.2120
Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome.
D. Silverman (2001)
10.1016/S0304-3940(02)01038-8
Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment
M. J. Leon (2002)
10.1001/ARCHNEUR.59.8.1267
Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.
K. Buerger (2002)
10.1016/S0165-0173(02)00158-3
Dendritic Spine Pathology: Cause or Consequence of Neurological Disorders?
J. Fiala (2002)
10.1136/jnnp.73.4.377
Abnormal verbal event related potentials in mild cognitive impairment and incipient Alzheimer's disease
J. Olichney (2002)
10.1001/ARCHNEUR.59.11.1729
Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.
M. Riemenschneider (2002)
10.1016/S0002-9440(10)62554-0
Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay.
Y. Hu (2002)
10.1176/APPI.AJP.159.5.738
Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.
G. Alexander (2002)
10.1212/WNL.59.4.627
CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects
K. Buerger (2002)
10.1093/clinchem/48.2.375
Immunoassay for serum glutamine synthetase in serum: development, reference values, and preliminary study in dementias.
Miyoko Takahashi (2002)
10.1016/S0022-510X(03)00229-6
The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia
W. Lojkowska (2003)
10.1016/S0896-6273(03)00124-7
APP Processing and Synaptic Function
Flavio Kamenetz (2003)
10.1016/S1474-4422(03)00530-1
CSF markers for incipient Alzheimer's disease
K. Blennow (2003)
10.1002/jnr.10599
Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease
J. Sáez-Valero (2003)
10.1001/JAMA.289.16.2094
Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
T. Sunderland (2003)
10.1212/01.WNL.0000063311.58879.01
Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease
P. Giannakopoulos (2003)
10.1007/s00259-003-1194-1
Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study
A. Drzezga (2003)
10.1212/01.WNL.0000091890.32140.8F
Plasma A&bgr;40 and A&bgr;42 and Alzheimer’s disease: Relation to age, mortality, and risk
R. Mayeux (2003)
10.1007/BF00689591
A variety of cerebral amyloid deposits in the brains of the Alzheimer-type dementia demonstrated byβ protein immunostaining
H. Yamaguchi (2004)
10.1001/ARCHPSYC.61.1.95
Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
H. Hampel (2004)
10.1002/ana.20009
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
William E. Klunk (2004)
10.1212/01.WNL.0000115115.98960.37
Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain
M. Ingelsson (2004)
10.1093/BRAIN/AWH101
Age-related cortical grey matter reductions in non-demented Down's syndrome adults determined by MRI with voxel-based morphometry.
S. Teipel (2004)
10.1212/01.WNL.0000106466.09835.46
Differential aging of the medial temporal lobe
N. Raz (2004)
10.1111/j.1365-2796.2004.01368.x
CSF biomarkers for mild cognitive impairment
K. Blennow (2004)
10.1007/BF00308809
Neuropathological stageing of Alzheimer-related changes
H. Braak (2004)
10.1016/j.neuroimage.2005.05.015
Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: A longitudinal MRI study
G. Chételat (2005)
10.1212/01.WNL.0000160089.43264.1A
MRI predictors of risk of incident Alzheimer disease
T. Stoub (2005)
10.1523/JNEUROSCI.2177-05.2005
Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory
R. Buckner (2005)
10.1136/jnnp.2004.035600
A voxel based morphometry study on mild cognitive impairment
C. Pennanen (2005)
10.1176/APPI.AJP.162.4.676
Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?
M. Hashimoto (2005)
10.1097/01.WNP.0000173559.60113.AB
Usefulness of P300 in Subjective Memory Complaints: A Prospective Study
A. Gironell (2005)
10.1136/jnnp.2004.036566
EEG coherence reflects regional corpus callosum area in Alzheimer’s disease
O. Pogarell (2005)
10.1093/CERCOR/BHH200
Focal decline of cortical thickness in Alzheimer's disease identified by computational neuroanatomy.
J. Lerch (2005)
10.1136/jnnp.2004.038729
Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer’s disease
N. Bohnen (2005)
10.1002/ana.20503
Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia
C. Zarow (2005)
10.1016/j.neuron.2005.10.028
Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo
J. Cirrito (2005)
10.1212/01.wnl.0000180958.22678.91
Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI
C. Jack (2005)
10.1212/01.wnl.0000228230.26044.a4
[11C]PIB in a nondemented population
M. Mintun (2006)
10.1056/NEJMOA054625
PET of brain amyloid and tau in mild cognitive impairment.
G. Small (2006)
10.1016/S1474-4422(06)70501-4
Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study
M. Oijen (2006)
10.1093/BRAIN/AWL178
Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
H. Engler (2006)
10.1016/j.jns.2006.09.014
CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment
A. Stefani (2006)
10.1016/j.neurobiolaging.2005.07.021
Prediction of longitudinal cognitive decline in normal elderly with subjective complaints using electrophysiological imaging
L. Prichep (2006)
10.1016/S1474-4422(06)70355-6
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
O. Hansson (2006)
10.1002/ana.20730
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans
Anne M. Fagan (2006)
10.1097/01.wad.0000191420.61260.a8
The Role of Biomarkers in Clinical Trials for Alzheimer Disease
L. Thal (2006)
10.1016/j.neuroscience.2006.08.049
Conversion from mild cognitive impairment to Alzheimer’s disease is predicted by sources and coherence of brain electroencephalography rhythms
P. Rossini (2006)
10.1016/j.neurobiolaging.2006.08.004
Transcriptional profiling of Alzheimer blood mononuclear cells by microarray
O. Maes (2007)
10.1212/01.wnl.0000256043.50901.e3
Fluctuations of CSF amyloid-&bgr; levels: Implications for a diagnostic and therapeutic biomarker
R. Bateman (2007)
10.1142/S0219635207001374
Rates of decline distinguish Alzheimer's disease and mild cognitive impairment relative to normal aging: integrating cognition and brain function.
B. Liddell (2007)
10.1097/rct.0b013e31802f4139
Automated Measurement of Hippocampal Atrophy Using Fluid-Registered Serial MRI in AD and Controls
J. Barnes (2007)
10.1196/annals.1379.012
Imaging and CSF Studies in the Preclinical Diagnosis of Alzheimer's Disease
M. D. de Leon (2007)
10.1017/S0317167100005618
Biological Markers in Alzheimer's Disease
Peter Bailey (2007)
10.1385/MN:24:1-3:087
CSF total tau, Aβ42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease
K. Blennow (2001)
10.1038/nm1653
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Sandip Ray (2007)
10.1212/01.wnl.0000261919.22630.ea
Imaging β-amyloid burden in aging and dementia
C. Rowe (2007)
10.1016/j.neuroimage.2007.07.008
Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment
S. Teipel (2007)
10.1016/j.neurobiolaging.2006.05.006
CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment
F. Bouwman (2007)
10.1038/nrn2194
Tau-mediated neurodegeneration in Alzheimer's disease and related disorders
C. Ballatore (2007)
10.1212/01.wnl.0000267428.62582.aa
CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment
G. Li (2007)
10.1002/prca.200600999
Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease
Yan Hu (2007)
10.1001/ARCHNEUR.64.3.NOC60123
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
A. Fagan (2007)
10.1212/01.wnl.0000244749.20056.d4
Amyloid, hypometabolism, and cognition in Alzheimer disease
P. Edison (2007)
10.1001/ARCHPSYC.64.6.718
Levels of β-Secretase (BACE1) in Cerebrospinal Fluid as a Predictor of Risk in Mild Cognitive Impairment
Zhenyu Zhong (2007)
10.1073/pnas.0801227105
Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition
John S. K. Kauwe (2008)
10.1017/S1092852900017193
Taking the Next Steps in the Diagnosis of Alzheimer's Disease: The Use of Biomarkers
S. DeKosky (2008)
10.1373/clinchem.2008.104497
The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients.
J. Lee (2008)
10.1007/s00415-008-0750-9
Volumetric MRI and cognitive measures in Alzheimer disease
B. Ridha (2008)
10.1002/jmri.21049
The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods
C. Jack (2008)
10.1016/j.jalz.2007.10.008
Electroencephalography and event-related potentials as biomarkers of mild cognitive impairment and mild Alzheimer’s disease
C. E. Jackson (2008)
10.1007/s00702-008-0177-6
Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease
Volker Welge (2009)
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease*
Harald Hampel (2008)
10.1001/jama.2009.1064
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
N. Mattsson (2009)
10.1126/science.1180962
Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle
Jae-Eun Kang (2009)
10.1016/j.neuron.2009.07.003
Amyloid Deposition Is Associated with Impaired Default Network Function in Older Persons without Dementia
R. Sperling (2009)
10.1212/WNL.0b013e3181bc010c
Relationships between biomarkers in aging and dementia
W. Jagust (2009)
10.1002/ana.21610
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
L. Shaw (2009)
10.1016/j.neurobiolaging.2007.08.010
Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment
M. Brys (2009)
10.1002/emmm.200900048
Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease
A. Fagan (2009)
10.1002/ana.21694
Cerebrospinal fluid amyloid β40 is decreased in cerebral amyloid angiopathy
M. Verbeek (2009)
10.2967/jnumed.109.065284
Preclinical Properties of 18F-AV-45: A PET Agent for Aβ Plaques in the Brain
S. Choi (2009)
10.1212/WNL.0b013e3181af79e5
MRI and CSF biomarkers in normal, MCI, and AD subjects
P. Vemuri (2009)
10.1016/j.jalz.2009.04.088
PET imaging of β-amyloid with florpiramine F18 (18F-AV-45): Preliminary results from a phase II study of cognitively normal elderly subjects, individuals with mild cognitive impairment, and patients with a clinical diagnosis of Alzheimer's disease
R. Sperling (2009)
10.1001/archneurol.2009.55
Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.
B. Snider (2009)
10.2174/156720509788929273
Baseline MRI Predictors of Conversion from MCI to Probable AD in the ADNI Cohort
S. Risacher (2009)
10.1212/WNL.0b013e3181af79fb
MRI and CSF biomarkers in normal, MCI, and AD subjects
P. Vemuri (2009)
10.1002/ana.21598
Amyloid imaging in mild cognitive impairment subtypes
D. Wolk (2009)
10.1371/journal.pone.0004183
S100A7, a Novel Alzheimer's Disease Biomarker with Non-Amyloidogenic α-Secretase Activity Acts via Selective Promotion of ADAM-10
W. Qin (2009)
10.1016/j.neurobiolaging.2008.06.016
Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: A longitudinal study
J. Sluimer (2010)
10.1212/WNL.0b013e3181cb3e25
Alzheimer's Disease Neuroimaging Initiative (ADNI)
R. Petersen (2010)
10.1016/j.biopsych.2009.08.024
Amyloid Plaques Disrupt Resting State Default Mode Network Connectivity in Cognitively Normal Elderly
Y. Sheline (2010)
10.1602/neurorx.1.2.213
Cerebrospinal fluid protein biomarkers for Alzheimer’s disease
K. Blennow (2004)



This paper is referenced by
10.1155/2020/5756382
Dielectric Constant and Conductivity of Blood Plasma: Possible Novel Biomarkers for Alzheimer's Disease
E. Dallé (2020)
10.1177/1177271920976367
Biomarkers: Our Path Towards a Cure for Alzheimer Disease
R. Tarawneh (2020)
Discovering Biomarkers of Alzheimer's Disease by Statistical Learning Approaches
Jintao Long (2019)
10.1016/j.bbrc.2017.11.122
Cerebrospinal fluid CD4+ T lymphocyte-derived miRNA-let-7b can enhances the diagnostic performance of Alzheimer's disease biomarkers.
Y. Liu (2018)
10.1111/jnc.14256
Shared pathological pathways of Alzheimer's disease with specific comorbidities: current perspectives and interventions
C. Nday (2018)
10.1016/j.schres.2016.10.040
Reduced superoxide dismutase-1 (SOD1) in cerebrospinal fluid of patients with early psychosis in association with clinical features
J. Coughlin (2017)
10.1001/jamaneurol.2016.0086
Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
R. Tarawneh (2016)
10.1016/j.abb.2016.03.017
Aβ40 has a subtle effect on Aβ42 protofibril formation, but to a lesser degree than Aβ42 concentration, in Aβ42/Aβ40 mixtures.
Shana E Terrill-Usery (2016)
10.1001/jamaneurol.2015.0202
Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
R. Tarawneh (2015)
10.1074/jbc.M115.679993
Validation and Characterization of a Novel Peptide That Binds Monomeric and Aggregated β-Amyloid and Inhibits the Formation of Neurotoxic Oligomers*
R. Barr (2015)
10.1021/bi500957g
Biophysical comparison of soluble amyloid-β(1-42) protofibrils, oligomers, and protofilaments.
M. Nichols (2015)
10.1016/j.ejphar.2015.02.047
Regulation of nicotinic acetylcholine receptors in Alzheimer׳s disease: a possible role of chaperones.
S. Sadigh-Eteghad (2015)
10.1024/0040-5930/a000675
[Cerebrospinal fluid markers in early diagnosis of Alzheimer dementia].
J. Wiltfang (2015)
10.1007/s11064-015-1631-0
Abnormal Glucose Metabolism in Alzheimer’s Disease: Relation to Autophagy/Mitophagy and Therapeutic Approaches
Kalpita Banerjee (2015)
10.1186/s13195-015-0105-6
Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort
(2015)
10.1016/j.biopsych.2014.08.024
Imaging Biomarkers Associated With Cognitive Decline: A Review
J. McConathy (2015)
10.1007/s12031-015-0667-6
Combined Genome-Wide CSF Aβ-42’s Associations and Simple Network Properties Highlight New Risk Factors for Alzheimer’s Disease
M. Souza (2015)
Klinisch-validierte molekulare Biomarker neurodegenerativer Demenzerkrankungen
Klinik für Psychiatrie (2014)
10.1007/978-3-319-07989-9
Atlas of Biomarkers for Alzheimer's Disease
M. González (2014)
10.1016/j.bcp.2013.11.009
Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020.
H. Hampel (2014)
Neuroinflammation in Alzheimer's disease: chemokines produced by astrocytes and chemokine receptors.
Chang Liu (2014)
10.3926/OMS.55
La aplicación de biomarcadores a la búsqueda de nuevas farmacoterapias para el tratamiento de la enfermedad de Alzheimer
Alcibiades E. Villarreal (2014)
10.1093/hmg/ddu372
SUCLG2 identified as both a determinator of CSF Aβ1-42 levels and an attenuator of cognitive decline in Alzheimer's disease.
A. Ramírez (2014)
10.1007/s00115-014-4177-5
Neue diagnostische Methoden bei Demenzen
J. Wiltfang (2015)
SUCLG 2 identified as both a determinator of CSF A b 1 – 42 levels and an attenuator of cognitive decline in Alzheimer ’ s disease
A. Ramirez (2014)
10.1016/j.gene.2014.05.031
Genetic markers for diagnosis and pathogenesis of Alzheimer's disease.
D. Kim (2014)
10.1007/978-3-319-07989-9_3
Tracking the Progression
M. M. González (2014)
10.1007/s00115-014-4086-7
Klinisch-validierte molekulare Biomarker neurodegenerativer Demenzerkrankungen
J. Wiltfang (2014)
10.1016/j.neuron.2014.08.048
Deficiency in LRP6-Mediated Wnt Signaling Contributes to Synaptic Abnormalities and Amyloid Pathology in Alzheimer’s Disease
Chia-Chen Liu (2014)
10.1212/WNL.0b013e3182a55fe3
Amyloid imaging
A. Lerner (2013)
10.1016/j.jtbi.2013.06.013
Computational studies on Alzheimer's disease associated pathways and regulatory patterns using microarray gene expression and network data: revealed association with aging and other diseases.
Priya P. Panigrahi (2013)
10.3389/fnmol.2013.00038
Erratum: Circulating microRNAs in Alzheimer's disease: the search for novel biomarkers
Véronique Dorval (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar